ERBB2 and triple-negative breast carcinoma: After adjusting for all these factors, we still identified that HER2-overexpressing and triple negative breast cancer patients were less likely to be treated with postmastectomy reconstruction compared with HR+/HER2− or HR+/HER2+ patients (HER2-overexpressing: OR (95% CI) 0.896 (0.817–0.984), P = 0.021; triple negative: OR (95% CI) 0.806 (0.751–0.866), P < 0.001, Table 2).